• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Humanized antibody produces marked improvement in plaque psoriasis

Article

Washington - The humanized monoclonal antibody efalizumab, given once weekly subcutaneously, produces profound clinical improvement in moderate to severe plaque psoriasis, reported Craig Leonardi, M.D., at the American Academy of Dermatology's 59th annual meeting.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.